What the business is, and whether it's a good one at a fair price.
Sells generic pharmaceutical formulations, including injectable products made by subsidiary Caplin Steriles Limited, primarily to customers in emerging markets and the United States. The 'Rest of the World' segment accounts for 75.3% of segment revenue and the USA segment 19.7%, with a small unallocated portion of 5.0%. The US business operates through Caplin Steriles, which holds 55 ANDA approvals from the USFDA, including a May 2026 approval for Foscarnet Sodium Injection, a generic version of Foscavir targeting a US market of approximately $15 million for the 12 months ending March 2026. On the cost side, materials account for 16.3% of revenue, employee costs 9.1%, and other operating expenses 16.5%, with capex at 11.3% of revenue. The company holds ₹1,471 crores in free cash reserves and ₹2,726 crores in liquid assets, and declared an interim dividend of ₹4 per share (200% on face value of ₹2) for FY26.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from CAPLIN POINT LAB LTD.'s filed financials and exchange disclosures
CAPLIN POINT LAB LTD. is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol CAPLIPOINT.
Yes. Over the trailing twelve months CAPLIN POINT LAB LTD. reported a net profit of ₹678 Cr on revenue of ₹2,287 Cr.
Yes. The dividend yield is 0.22% at the current price. It paid out 7% of its profit as dividend in FY26.
Effectively yes. It holds ₹94 Cr more cash than debt. Debt stands at 0.00× equity.
On trailing P/E, CAPLIN POINT LAB LTD. ranks 90 of 169 in Pharmaceuticals — cheaper than 47% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session CAPLIN POINT LAB LTD. moves 1.16% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by CAPLIN POINT LAB LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
